DEVELOPMENTAL PATHWAY FUNDING SCHEME: MAR 2021

1. Title: DEVELOPMENTAL PATHWAY FUNDING SCHEME: MAR 20212. Awarding Authority: Medical Research Council (MRC), GB Email: tim.ellis@mrc.ukri.org. Web: (Dr. Tim Ellis)3. Contract type: Service contract4. Description: Developmental pathway funding scheme: Mar 2021You can apply for academically led translational projects that aim to improve prevention, diagnosis, prognosis or treatment of significant health needs, or to develop research tools that increase the efficiency of developing interventions. All diseases and interventions are eligible for support. You can also address global health issues.Support is available for the following stages of development:prototype discovery and designpre-clinical testing of novel interventionsearly-phase clinical studies of novel interventions (phases 1 and 2a).Your projects can start and finish at any point. You can submit follow-on proposals where you can justify the need for continued support.You can apply for funding for work in:candidate therapeutic entities, for example drug discoveryvaccines for infectious or non-infectious diseasenovel biologics (antibodies, peptides, proteins)advanced therapeutics (gene therapy, T-cell therapy, etc)regenerative medicinerepurposing clinical studies, using existing therapies for new indicationsnovel devicesdiagnostics (including biomarker validation)novel medical imaging technologynew surgical techniques or toolsbehavioural and psychological interventionsdigital healthcare, app development, enabled devices, artificial intelligence enabled diagnosisradiotherapy and radiation protocolsinterventions that benefit health in low- and middle-income countries.This funding opportunity will not support:fundamental or investigative research not linked to a development plan (supported by the MRC research boards)clinical studies where the main aim is to investigate disease mechanism (supported by the MRC research boards)late-phase clinical trials (supported by MRC-NIHR efficacy and mechanism evaluation and NIHR health technology assessment programmes)late-phase global health trials (supported by the Applied Global Health Research Board).There is no limit to the amount of funding you can apply for or the length of your project. You should instead justify the timescale and resources needed in the context of the proposed work.CollaborationsWe encourage working with charities or industry where these partnerships can add value to the project, for example in terms of access to expertise, technologies, reagents or funding. Please note that collaboration is not a prerequisite for application.Applications involving collaboration with industry should consult the MRC industry collaboration agreement. Please note that we do not fund the work of your industrial partners.5. CPV Code(s): 73110000, 73100000, 73000000, 732200006. NUTS code(s): UKK, UKK1, UKK147. Main site or location of works, main place of delivery or main place of performance: South West (England), Gloucestershire, Wiltshire And Bristol/Bath Area, Swindon.8. Reference attributed by awarding authority: Not provided.9. Estimated value of requirement: Total fund: £30,000,00010. Closing date: 24.3.2021 (16:00).11. Address to which they must be sent: For further information regarding the above contract notice please visit:12. Other information: Funding type: GrantOpening date: 12 February 2021You can apply for funding from this scheme for academically led pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including repurposing of existing therapies.Awards are made every year and there are deadlines every four months. We generally fund 80% of the full economic costs of your research, and your research organisation must agree to find the balance.Please refer the website above for documentationTKR-2021210-EX-1553586# funding opportunity